News & Events

20 January 2025

A-TANGO joins the X-odus: Follow us on Bluesky instead

Like many other academic institutions and science projects, we recently decided to delete our project account on the social media platform X. Instead, you can now follow A-TANGO on Bluesky Social.

It's very easy: Just click on the link above or scan the QR code in the image, set up an account, and follow us. From the beginning of the project, we always wanted to feed two different social media platforms. Our account on LinkedIn remains the same and also presents frequent project-related updates.

10 January 2025

Troels Jordansen becomes new CEO of Yaqrit

Yaqrit welcomes Troels Jordansen as its new CEO. With over 30 years of international healthcare experience spanning pharmaceuticals, medical devices, cellular therapy, and biotech, Troels brings a strong commercial background in sales, marketing, investor relations, and business development. Having co-founded start-ups and led public companies, he has raised over €200 million in funding and closed deals exceeding €500 million. His global expertise will also be instrumental in driving A-TANGO’s innovation. Read the related press release.

19 December 2025

2024 in Review - Happy Holidays!

We wish everyone a relaxing holiday season and a great start of the new year! For A-TANGO, it was an eventful year, including an important amendment, a detailed periodic report, networking with stakeholders and presenting results at EASL Congress in Milan, a fantastic public masterclass on market access and reimbursement in healthcare, new early-career scientist (ECS) videos, signing a new contract research organisation (CRO) on the project - KlinEra Global Services, establishing the first clinical study sites in the UK, and exploring the option to open further study sites in India. Also, a cordial thank you goes out to Arthur Mulle for his time and dedication as project manager until the end of November and a warm welcome to the new project manager, Dr. Christiana Krammer.

OUR VISION

More than 10 million people worldwide suffer from decompensated cirrhosis, often as a result of severe alcoholic hepatitis (sAH) or other chronic liver diseases. In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF), a syndrome characterized by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. We call this novel combinatorial therapy G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.

Read more

OBJECTIVES

  • Obtain ethical and regulatory approval of the planned clinical studies
  • Ensure safe and regulated supply of the required drugs and placebos
  • European multicenter clinical study to establish the safety, pharmacokinetics, and efficacy of our novel therapeutic strategy
  • Explore the pathophysiological mechanisms and evaluate biomarkers
  • Evaluate our results with respect to clinical outcome, treatment impact, and quality of life
  • Exploit our results by identifying economic benefits for the healthcare system, reimbursement strategies, and potential commercial interest
  • Disseminate the therapeutic potential of our novel treatment strategy to stakeholders and increase awareness of end-stage liver disease

Read more

SCIENTIFIC COORDINATOR

Prof. Dr. Rajiv Jalan (EF CLIF)
Av. Diagonal 477, 11th floor
08036 Barcelona
Spain

CLINICAL STUDY SUPERVISOR

Dr. med. Cornelius Engelmann (MD, PhD) (Charité)
Augustenburger Platz 1
13353 Berlin
Germany

PROJECT
MANAGEMENT

concentris research management gmbh
Ludwigstr. 4
82256 Fürstenfeldbruck
Germany